Daiichi Sankyo begins phase 2 study of DS─8201 in patients with advanced HER2─overexpressing/HER2─mutated non─squamous NSCLC

Daiichi Sankyo Company, Limited announced that the first patient has been dosed in a global phase 2 study evaluating the efficacy and safety of DS─8201, an investigational HER2─targeting antibody drug conjugate (ADC)

More From BioPortfolio on "Daiichi Sankyo begins phase 2 study of DS─8201 in patients with advanced HER2─overexpressing/HER2─mutated non─squamous NSCLC"